Revenue

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Rybelsus Revenue	23.71B	23.30B
Ozempic Revenue	129.12B	120.34B
Victoza Revenue	4.02B	5.48B
Total GLP-1 Revenue	156.85B	149.13B
Long-Acting Insulin Revenue	19.21B	19.10B
Premix Insulin Revenue	10.67B	10.79B
Fast-Acting Insulin Revenue	19.72B	18.52B
Human Insulin Revenue	6.02B	6.97B
Total Insulin Revenue	55.62B	55.37B
Other Diabetes Care Revenue	1.86B	2.12B
Total Diabetes Care Revenue	214.33B	206.62B
Wegovy Revenue	77.11B	58.21B
Saxenda Revenue	4.20B	6.94B
Total Obesity Care Revenue	81.31B	65.15B
Diabetes & Obesity Care Revenue	295.64B	271.76B
Rare Blood Disorders Revenue	12.33B	12.14B
Rare Endocrine Disorders Revenue	6.05B	4.99B
Other Rare Disease Revenue	1.58B	1.51B
Rare Disease Revenue	19.96B	18.64B
Revenue (Total)	315.60B	290.40B

Revenue by Geography

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
US Revenue	180.79B	167.40B
EUCAN Revenue	64.40B	57.55B
Emerging Markets Revenue	30.16B	29.52B
APAC Revenue	21.05B	17.44B
China Revenue	19.20B	18.50B
Total International Revenue	134.81B	123.00B
Revenue (Other)	-134.81B	-123.00B
Revenue (Total)	315.60B	290.40B

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
US Revenue (Pre-FY2024 Reporting)	156.42B	167.40B
Other North American Operations (NAO) Revenue	-	10.77B
Total North American Operations (NAO) Revenue	-	178.17B
EMEA Revenue	-	60.40B
China Revenue (Pre-FY2024 Reporting)	19.20B	18.50B
Rest of World Revenue	-	33.33B
Revenue (Total)	315.60B	290.40B

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Diabetes & Obesity Care Operating Profit	131.44B	127.72B
Rare Disease Operating Profit	1.22B	620.00M
Operating Income (Total)	132.66B	128.34B

Updated Sep 30, 2025. Data Source: Fiscal.ai.